Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768303 | 0.85 | RAB9A (0.41) | NPC1RAB9AHIF1AMAPTSMN1; SMN2 | |
| SCHEMBL2770586 | 0.82 | MAOB (0.41) | NPC1RAB9AHIF1AMAPTSMN1; SMN2 | |
| SCHEMBL2770003 | 0.81 | NPC1 (0.45) | NPC1RAB9AHIF1AMAPTSMN1; SMN2 | |
| SCHEMBL2768687 | 0.80 | HIF1A (0.41) | NPC1RAB9AHIF1AMAPTSMN1; SMN2 | |
| SCHEMBL2769006 | 0.80 | HPGD (0.43) | NPC1RAB9AHIF1AMAPTSMN1; SMN2 | |
| SCHEMBL2768099 | 0.78 | MAPT (0.47) | NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL2768264 | 0.78 | SMN1; SMN2 (0.42) | NPC1RAB9AHIF1AMAPTSMN1; SMN2 | |
| SCHEMBL2768827 | 0.77 | SMN1; SMN2 (0.45) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL2767619 | 0.77 | MAPT (0.47) | NPC1RAB9AHIF1AMAPTSMN1; SMN2 | |
| SCHEMBL2768067 | 0.77 | SSTR4 (0.40) | NPC1RAB9AHIF1AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881967-B1 | SUBSTITUTED BENZO(D)ISOXAZOL-3-YL AMINE COMPOUNDS AS ANALGESICS | GRUENENTHAL GMBH (DE) | 2010-04-28 | — | — | EP | claimed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | claimed |
| US-7696238-B2 | Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics | GRUENENTHAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | KCNQ1, KCNQ2, KCNQ3 | NPC1 2230/4885RAB9A 3127/4885HIF1A 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.